Background
Methods
Patients
No. | Age range (years) | Location | Diagnosis | Pathological fracture (yes/no) | Resection length (mm) | Plate used (yes/no) | Followup (months) | Complications | MSTS score |
---|---|---|---|---|---|---|---|---|---|
1 | > 80 | Ulna | Undifferentiated sarcoma | Yes | 60 | No | 38 | None | 28 |
2 | 41–50 | Humerus | Prostate cancer | Yes | 80 | Yes | 16 | None | 21 |
3 | 61–70 | Humerus | Rectal cancer | Yes | 90 | Yes | 6 | Radial nerve injuries | 15 |
4 | 61–70 | Humerus | Lung cancer | No | 90 | No | 10 | Aseptic loosening loosening 4 mm | 20 |
5 | 71–80 | Humerus | Multiple myeseloma | Yes | 90 | Yes | 3 | None | 18 |
6 | 51–60 | Humerus | Lung cancer | Yes | 80 | Yes | 3 | None | 17 |
7 | 51–60 | Humerus | Lung cancer | No | 80 | No | 8 | None | 19 |
8 | > 80 | Humerus | Liver cancer | Yes | 80 | No | 4 | None | 16 |
9 | 61–70 | Humerus | Breast cancer | Yes | 60 | No | 17 | None | 23 |
10 | 51–60 | Humerus | Lung cancer | No | 80 | No | 13 | None | 22 |
11 | 61–70 | Humerus | Multiple myeseloma | Yes | 85 | No | 26 | Aseptic loosening | 25 |
12 | 71–80 | Humerus | Lung cancer | No | 75 | No | 22 | None | 22 |
13 | 41–50 | Humerus | Prostate cancer | Yes | 80 | Yes | 12 | None | 22 |
14 | 61–70 | Humerus | Rectal cancer | Yes | 90 | No | 6 | Radial nerve injuries | 15 |
15 | 51–60 | Femur | Lung cancer | Yes | 80 | No | 4 | None | 22 |
16 | 71–80 | Femur | Rectal cancer | Yes | 100 | No | 3 | None | 19 |
17 | 51–60 | Femur | Liver cancer | Yes | 110 | No | 4 | None | 19 |
18 | 31–40 | Femur | Osteosarcoma | Yes | 110 | No | 25 | Tumor recurrence | 16 |
19 | 51–60 | Femur | Breast cancer | Yes | 160 | Yes | 36 | None | 27 |
20 | 71–80 | Femur | Rectal cancer | Yes | 90 | No | 8 | None | 22 |
21 | 61–70 | Femur | Renal cancer | Yes | 80 | No | 9 | None | 24 |
22 | 61–70 | Femur | Lung cancer | Yes | 120 | No | 10 | None | 26 |
23 | 51–60 | Femur | Renal cancer | Yes | 80 | No | 14 | None | 22 |
24 | 61–70 | Femur | Breast cancer | Yes | 80 | Yes | 7 | None | 20 |
25 | 61–70 | Femur | Liver cancer | Yes | 80 | No | 4 | None | 19 |
26 | 61–70 | Femur | Lung cancer | Yes | 100 | No | 9 | None | 21 |
27 | 61–70 | Femur | Lung cancer | Yes | 80 | No | 3 | Angulation | 21 |
28 | 71–80 | Femur | Multiple myeseloma | Yes | 120 | No | 10 | None | 25 |
29 | 71–80 | Femur | Unknown source cancer | Yes | 70 | Yes | 3 | Incision delayesed healing | 15 |
30 | 71–80 | Femur | Non-Hodgkin lyesmphoma | Yes | 150 | Yes | 10 | None | 19 |
31 | 71–80 | Femur | Lung cancer | Yes | 90 | Yes | 8 | None | 16 |
32 | 51–60 | Femur | Lung cancer | No | 80 | No | 12 | None | 22 |
33 | 61–70 | Femur | Lung cancer | No | 100 | No | 7 | None | 18 |
34 | 51–60 | Femur | Lung cancer | No | 120 | No | 15 | None | 27 |
35 | > 80 | Femur | Renal cancer | Yes | 80 | No | 79 | None | 28 |
36 | 71–80 | Femur | Renal cancer | Yes | 100 | No | 38 | None | 27 |
37 | 51–60 | Femur | Breast cancer | Yes | 60 | No | 3 | None | 19 |
38 | 41–50 | Femur | Lung cancer | No | 120 | No | 14 | None | 24 |
39 | 10–20 | Femur | Osteosarcoma | Yes | 190 | No | 3 | None | 18 |
40 | 71–80 | Femur | Breast cancer | Yes | 60 | No | 6 | None | 19 |
41 | 71–80 | Femur | Renal cancer | Yes | 80 | No | 3 | None | 16 |
42 | 51–60 | Femur | Lung cancer | Yes | 80 | No | 4 | None | 17 |
43 | 71–80 | Femur | Unknown source cancer | Yes | 70 | Yes | 23 | Incision delayesed healing | 20 |
44 | 71–80 | Femur | Non-Hodgkin lyesmphoma | Yes | 80 | No | 46 | None | 27 |
45 | 41–50 | Tibia | Langerhans cell sarcoma | No | 100 | No | 21 | Tumor recurrence | 10 |
46 | 61–70 | Tibia | Undifferentiated sarcoma | No | 100 | No | 13 | Incision delayesed healing | 18 |
47 | 61–70 | Tibia | Unknown source cancer | Yes | 60 | Yes | 21 | None | 22 |
48 | 41–50 | Tibia | Soft tissue sarcoma | No | 100 | No | 7 | Tumor recurrence | 20 |
49 | 51–60 | Tibia | Osteosarcoma | No | 130 | No | 7 | None | 19 |
Statistical analysis
Results
Type of failure | Number of patients (%) |
---|---|
I (soft tissue failure) | 5(10.2%) |
II (aseptic loosening) | 2(4.1%) |
III (structural failure) | 1(2.0%) |
IV (infection) | 0(0%) |
V (tumor progression) | 3(6.1%) |